|
- Janssen
Janssen Global Trial Finder; World Without Disease Accelerator; Janssen Clinical Innovation; Precision Medicine Janssen Diagnostics
- A Study of Amivantamab Alone or in Addition to Other . . . - Janssen
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent metastatic head and neck cancer The study will also confirm the recommended Phase 2 combination dose (RP2CD) for
- Janssen | 2022 Transparency Report
Through the 2022 Janssen U S Transparency Report, we continue our legacy of contributing insights, data and real-world evidence to help inform and advance policy solutions to create a more sustainable, equitable and innovative healthcare system
- Privacy Policy section - Janssen CarePath
Janssen Pharmaceuticals, Inc , recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country
- A Study of JNJ-64042056 in Participants With Preclinical . . . - Janssen
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo
- Efficacy and Safety Study of Nipocalimab for Adults With Chronic . . .
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A
- Acerca de Janssen | Janssen Centro América y Caribe
En Janssen abordamos la innovación desde el punto de vista científico, aplicada en 5 áreas terapéuticas: Oncología, En Janssen contribuimos con las comunidades donde operamos Johnson Johnson tiene un programa de responsabilidad social que opera desde 2004 en los diferentes países de
- A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting . . . - Janssen
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion)
|
|
|